camrelizumab + inetetamab + utidelone

This drug is a combination therapy consisting of three agents: - Camrelizumab is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor. It acts as an immune checkpoint inhibitor by blocking PD-1 interaction with its ligand PD-L1, thereby activating T cells to mount an anti-tumor immune response. It is developed primarily for hepatocellular carcinoma and other cancers such as Hodgkin lymphoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, non-small cell lung cancer, and triple-negative breast cancer. Camrelizumab has shown promising antitumor activity and manageable toxicities. - Inetetamab is a monoclonal antibody targeting HER2 (human epidermal growth factor receptor 2), used in HER2-positive cancers such as breast cancer. It binds to the extracellular domain of HER2 to inhibit tumor growth signaling pathways. - Utidelone is a small molecule epothilone analog that stabilizes microtubules and inhibits their depolymerization, leading to cell cycle arrest and apoptosis in cancer cells. It is used mainly in metastatic breast cancer treatment.

Other names

camrelizumab + inetetamab + utidelone